Navigation Links
Elbit Medical Imaging Ltd. Announces Publication of a Prospectus in Israel
Date:9/11/2007

ember 31 and on July 1 of each year between 2007 and 2021. The first interest payment will be made in December 31, 2007 and the last interest payment is due in July 1, 2021. The principal amount of Series F Notes will be repayable in six equal annual installments commencing on October 1, 2010 and ending on October 1, 2015. Interest will be paid in semi-annual installments on April 1 and on October 1 of each year between 2008 and 2015. The first interest payment will be made on April 1, 2008 and the last interest payment is due on October 1, 2015.

The Series E Notes and Series F Notes were rated A1 by Midroog Ltd. (a credit-rating agency affiliated with Moody's Investors Services), on a local scale, and were rated A+/Stable by Maalot The Israel Securities Rating Company Ltd. (a credit rating agency affiliated with Standard & Poor's), on a local scale.

The publication of the Prospectus followed the approval by the Israel Securities Authority ("ISA").

The TASE gave its preliminary approval for the publication of the Offering Prospectus. Prior to the publication of the Complementary Notice, the Company will be required to receive the TASE's approval for the offering of each of the Series E and the Series F Notes. The listing of each of the Series E and the Series F Notes is subject to satisfaction of certain TASE's requirements regarding minimum public holdings and minimum dispersal.

The proposed public offering is expected to be completed during September 2007, although there is no guarantee that proposed offerings will be completed by such date or that they will be completed at all.

The securities offered have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Elbit Medical Imaging Ltd.

EMI is a subsidiary of Europe Israel (M.M.S.) Ltd. EMI's activities are
'/>"/>

SOURCE Elbit Medical Imaging Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...OWN, W.Va., Nov. 21 New...ng whether a smokeless, spitless tobacco product a...rchers have found that RJ Reynolds, Camel Snus - t...ction - contains surprisingly high levels of nicot... than most other snuff products," said Bruce Adkin...
(Date:11/21/2008)...A, S.C., Nov. 21 U.S. N...for Quality Assurance (NCQA) ranked BlueChoice(R) ...merica,s Best Health Plans(TM), published in U.S. ..., The respected annual ranking ranks the nation,...ber satisfaction and NCQA accreditation scores. NC...
(Date:11/21/2008)...E, N.J., Nov. 21 Barr Ph... that its shareholders overwhelmingly approved the...sition of Barr by Teva Pharmaceuticals Industries ...demonstrated the overwhelming support of the trans...wney, Barr,s Chairman and CEO. "We are pleased wit...
(Date:11/21/2008)...0 B.C., a new and deadly diseaseits cause remains ...state was teeming with citizens, soldiers and refu...rta. As streets filled with corpses, social order ... returned twice and Athens lost a third of its pop... marked the beginning of the end of the Golden Age...
Breaking Medicine News(10 mins):Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4
...therapeutic regimens are effective in suppressing ...nged treatment may be complicated by development o...spite // continued concerns over the safety of int... in clinical practice interrupt therapy for reason...
...te in vitro fertilization (IVF) baby of a single p...tions about the newborn's legal status and the sin... whose childless marriage had ended in divorce yea...ountry's first single father whose son was born th...
...obe University of Australia have found a new combi...he parasite responsible for causing malaria. They ...or treatment // helps in killing P. falciparum whi...hloroquine is a largely used drug in the treatment...
...most common breathing problems encountered by many...s been a considerable increase in the incidence of...as been estimated that nearly 196,000 children are...ry year with asthma attacks. A considerable amount...
Other Medicine News:Health News:A first for India - IVF baby born of surrogacy 2Health News:Improved parent-physician communication to prevent hospitalizations for childhood asthma 2
(Date:11/20/2008)..., Switzerland, November 20 /PRNewswire-FirstCall/ ...ti-infective Drugs Advisory Committee of the,U.S....o 2 against the,approval of intravenous iclaprim,...reatment of patients with complicated skin and ski...caused by methicillin-resistant Staphylococcus,au...
(Date:11/20/2008)... Calif., Nov. 20 Bionovo...ll present results from the Phase 1B,clinical tri...tatic breast,cancer, BZL101, at the Society for I...nce in Atlanta, Georgia. The Company,s oral prese...d will be presented as a part of the Best of the,...
(Date:11/20/2008)...Mass., Nov. 20 Radius Health ("Rad...onal $15 million to its second institutional finan...o $82.5 million and the total amount raised since ...sting institutional investors participated in the ...d including MPM Capital, The Wellcome Trust, Healt...
(Date:11/20/2008).... 20 PAREXEL Internation... biopharmaceutical services provider, today announ...provide regulatory consulting and clinical researc...ce, PAREXEL now has locations throughout five impo...which also include Argentina, Brazil, Chile, and M...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Mediterranean Diet May Ward Off Type 2 Diabetes 20660 1Mediterranean Diet May Ward Off Type 2 Diabetes 20660 2Mediterranean Diet May Ward Off Type 2 Diabetes 20660 3Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO 20657 1Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO 20657 2Technological Interventions Merge Into Health and Fitness 20654 1Technological Interventions Merge Into Health and Fitness 20654 2Technological Interventions Merge Into Health and Fitness 20654 3Brisk Walking Lowers Blood Pressure Increases Fitness in Obese 20651 1Brisk Walking Lowers Blood Pressure Increases Fitness in Obese 20651 2
...S WIRE)--Apr 26, 2007 - Northfield,Laboratories In...t,research organization has informed the Company t...l Phase III trauma trial with,PolyHeme(R), the Com...cell substitute, will not be complete until May., ...ories Inc. is a leader in developing an,oxygen-car...
... 0in 0pt; TEXT-ALIGN: left; tab-stops: 0in",align=...ops: list .5in; mso-list: l1 level1 lfo2">, <span ... MT,; mso-bidi-font-weight: bold">,Independent Jap...ng,Diovan to conventional therapy , , , ,<li st...so-list: l1 level1 lfo2">, <span style=,"FONT-SIZE...
Other Medicine Technology:Northfield Laboratories Investor Update 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 8Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 9Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 10Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 11Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 12
Take Performance to a Higher Level.
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC).
FemoStop plus system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic
... is used to seal the arterial puncture site. Duett...iotomy and the tissue tract with a flowable procoa...r and procoagulant - the Duett sealing device is d...he Duett is unique in its ability to quickly seal ...
Medicine Products: